{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-034129","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.738143+00:00","generated_at":"2026-06-03T19:06:25.931820+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Longeveron raises $6.2M from warrant exercise, total $11.4M; regains Nasdaq compliance","bullets":["Gross proceeds of ~$6.2M from exercise of 2,399,744 existing warrants at $2.35/share; combined with prior public offering totals ~$11.4M.","Issued new unregistered warrants to purchase up to 4,799,488 shares (Series C: 5-year term, Series D: 24-month term, both at $2.35 exercise price).","Intends to use net proceeds for clinical/regulatory development of Lomecel-B for HLHS, Alzheimer's, and general corporate purposes.","Regained compliance with Nasdaq minimum bid price requirement after closing price >=$1.00 for 13 consecutive business days through April 15, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-034129","json":"https://secwatch.observer/filing/0001213900-24-034129.json","markdown":"https://secwatch.observer/filing/0001213900-24-034129.md","text":"https://secwatch.observer/filing/0001213900-24-034129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/0001213900-24-034129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/ea0204043-8k_longeve.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T19:06:25.931820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"463d06276733e31291258ec3cbc1b20ac3cc6677","claim":"Longeveron Inc. entered into Inducement Letter Agreements with certain holders valued at approximately $6.2 million (effective 2024-04-16).","evidence_excerpt":"On April 16, 2024, Longeveron Inc., a Delaware corporation (the “Company”), entered into inducement letter agreements (the “Inducement Letter Agreements”) with certain holders (the “Holders”) of its existing (i) Series A warrants to purchase up to an aggregate of 242,425 shares of the Company’s Class A common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/0001213900-24-034129-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain holders"},{"label":"Value","value":"approximately $6.2 million"},{"label":"Effective","value":"2024-04-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}